Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebipenem Pivoxil Hydrobromide TQT Study
NCT04238195Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Jan 2020
- Primary completion
- Feb 2020
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tebipenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (4 arms), sponsored by Spero Therapeutics. Primary endpoint: Concentration-QT (C-QT) Relationship. Started Jan 2020; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT04238195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238195.